SPRB SPRUCE BIOSCIENCES, INC.

Nasdaq www.sprucebiosciences.com


$ 107.90 $ 2.85 (2.66 %)    

Friday, 31-Oct-2025 19:54:16 EDT
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 110.1
$ 107.26
$ 105.00 x 119
$ 114.00 x 141
$ 101.04 - $ 111.61
$ 0.10 - $ 240.00
220,757
na
61.99M
$ 5.67
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 04-15-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-18-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-16-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-10-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-14-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 05-12-2021 03-31-2021 10-Q
19 03-22-2021 12-31-2020 10-K
20 11-18-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 spruce-biosciences-may-offer-up-to-300m-in-securities

-SEC Filing

 jmp-securities-upgrades-spruce-biosciences-to-market-outperform-announces-254-price-target

JMP Securities analyst Jonathan Wolleben upgrades Spruce Biosciences (NASDAQ:SPRB) from Market Perform to Market Outperform ...

 kenneth-griffin-reports-999-passive-stake-in-spruce-biosciences-inc-as-of-oct-9

-SEC Filing

 reported-earlier-spruce-biosciences-reveals-500m-private-placement-financing

Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel ...

 spruce-biosciences-sprb-stock-jumps-30-after-hours-following-red-hot-rally-on-monday-heres-why

Spruce Biosciences shares soared after the FDA granted Breakthrough Therapy Designation to its lead treatment for Sanfilippo Sy...

 spruce-biosciences-stock-is-soaring-today-heres-why

Shares of Spruce Biosciences, Inc. (NASDAQ: SPRB) are surging Monday after the biotech company shared an important regulatory u...

 spruce-biosciences-says-fda-grants-breakthrough-therapy-designation-to-tralesinidase-alfa-enzyme-replacement-therapy-for-treatment-of-sanfilippo-syndrome-type-b

Breakthrough Therapy Designation Supported by Integrated Long-Term Clinical Data Demonstrating Normalization in Cerebral Spinal...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION